Treatment of chronic inflammatory disease with cytokines and anticytokines;Zytokin- und antizytokintherapien bei chronisch entzüindlichen darmerkrankungen

Deutsche Medizinische Wochenschrift

Volumn 126, Issue SUPPL. 1, 2001, Pages

  Wittig, B M ^a   Zeitz, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CD4 ANTIGEN; CORTICOSTEROID; CYTOKINE; CYTOKINE ANTIBODY; D2 E7; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; HUMAN; IMMUNE SYSTEM; REVIEW; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035365833     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-14492     Document Type: Review

References (57)

1. IFN-α and IFN-β: A link between immune memory and chronic inflammation
2. Administration of Infliximab in Crohn's disease does not deplete complement components C3 an C4
3. Control of cachectin (tumour necrosis factor) protects mice from lethal effect of endotoxin
4. The relationship between infliximab treatment and lymphoma in Crohn's disease
5. Regional specialization in the mucosal immune system; primed cells do not always home along the same track
6. T cells of the human intestinal lamina propria are high producers of interleukin-10
7. The engineered human antitumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis
8. Infliximab in Crohn's disease: First anniversary clinical experience
9. Etanercept (TNF receptor fusion protein, Enbrel) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
10. Distinct cytokine pattern in early and chronic ileal lesions of Crohn's diease
11. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
12. Suppression der Synthese des Tumornekrosefaktor
13. Treatment of ulcerative colitis with an engineered anti-TNFα antibody CDP571
14. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
15. Clinical experience with infliximab therapy in 100 patients with Crohn's disease
16. Recombinant human interleukin 10 in the treatment of patients with mild to moderate active Crohn's disease
17. Disparate CD4+ lamina propria lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
18. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease
19. Therapeutische monoklonale Antikörper
20. Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
21. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
22. Anti-TNF antibody in Crohn's disease - Status of information, comments and recommendations of an international working group
23. Targeting TNF alpha for the therapy of rheumatoid arthritis
24. Konventionelle und immunmodulatorische Therapie bei chronisch-entzündlichen Darmerkankungen
25. Infliximab-associated reversible cholestatic liver disease
26. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p-75)-Fc fusion protein
27. Antibodies to interleukin 12 abrogate established experimental colitis in mice
28. Mechanisms in failure of infliximab for Crohn's disease
29. Receptor-mediated label-transfer assay (RELAY) - A novel method for the detection of plasma tumor necrosis factor at attomolar concentrations
30. Infliximab for the treatment of fistulas in patients with Crohn's disease
31. Differential regulation of human T cell responsiveness by mucosal versus blood monocytes
32. Protection of recombinant human interleukin-11 against experimental TNB-induced colitis in rats
33. Successful management of Crohn's disease of the ileoanal pouch with infliximab
34. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa
35. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease
36. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
37. Therapy of inflammatory bowel disease
38. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
39. Chimeric monoclonal anti-tumor necrosis factor alpha antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis
40. T cell differentiation antigens on lymphocytes in human intestinal lamina propria
41. Which immunosuppressors do you use to treat Crohn's diseae and ulcerative colitis? In which order of priority and how worried are you about toxicity?
42. Safety and efficacy of recombinant human interleukin-10 chronic active Crohn's disease
43. Safety and tolerance of rHu-IL-10 treatment in patients with mild/moderate active ulcerative colitis
44. Twenty cases of peristomal pyoderma gangrenosum
45. Severe anaphylactic reaction to infliximab: Report of a case
46. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
47. Mucosal immune regulation and inflammatory bowel disease: New insights from murine models of inflammation
48. Immunological diseases of the gastrointestinal tract.I
49. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis
50. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
51. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
52. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
53. Treatment of Crohn's disease with interferon. A preliminary clinical trial
54. An open-label pilot study of low-dose thaliomide in chronically active, steroid-dependent Crohn's disease
55. Response to anti-TNFα-treatment is associated with the TNF-308.1 allele
56. Pathogenesis of inflammatory bowel disease
57. Phenotype and function of lamina propria T cells